Baxter International Inc. - Product Pipeline Review - 2012

Report Overview

Table of Contents

328.9

Select License Type

£328.90	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£657.79	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£986.69	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£328.90	Add to Wishlist
Change Currency	GBP EURO USD
	Order By Fax

Market	Healthcare and Medical
Report Type	Market Research
Country	Global
Published	28 May 2012
Number of Pages	225
Report Delivery	Email
Delivery Lead Time	1-3 hours, 24 hour max
Publisher	Global Markets Direct
File Format	PDF

Baxter International Inc. – Product Pipeline Review – 2012 - Global Market Direct's pharmaceuticals report, "Baxter International Inc. - Product Pipeline Review - 2012" provides data on the Baxter International Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Baxter International Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Baxter International Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Baxter International Inc. - Brief Baxter International Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Baxter International Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Baxter International Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Baxter International Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Baxter International Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Baxter International Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Baxter International Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Baxter International Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Baxter International Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Baxter International Inc.; Baxter International Inc. - Key Therapeutics; Baxter International Inc. - Pipeline Overview and Promising Molecules; Baxter International Inc. - News; Baxter International Inc. - Latest Updates; Baxter International Inc. - Pipeline; Baxter International Inc. - Discontinued/Dormant Projects

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

£328.90	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£657.79	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£986.69	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£328.90	Add to Wishlist
Change Currency	GBP EURO USD

Table of Contents
List of Tables
List of Figures
Baxter International Inc. Snapshot
Baxter International Inc. Overview
Key Information
Key Facts
Baxter International Inc. – Research and Development Overview
Key Therapeutic Areas
Baxter International Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Baxter International Inc. – Pipeline Products Glance
Baxter International Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Baxter International Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Baxter International Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Baxter International Inc. – Drug Profiles
Adult Autologous CD34+ Stem Cells
Product Description
Mechanism of Action
R&D Progress
Anti-MIF Antibody
Product Description
Mechanism of Action
R&D Progress
AV513
Product Description
Mechanism of Action
R&D Progress
BAX 855
Product Description
Mechanism of Action
R&D Progress
BAX-111
Product Description
Mechanism of Action
R&D Progress
Factor VIII
Product Description
Mechanism of Action
R&D Progress
Gammagard Liquid
Product Description
Mechanism of Action
R&D Progress
Gammagard Liquid + rHuPH20
Product Description
Mechanism of Action
R&D Progress
H1N1 Pandemic Influenza Vaccine
Product Description
Mechanism of Action
R&D Progress
H1N1 Pandemic Influenza Vaccine + Seasonal Trivalent Influenza Vaccine
Product Description
Mechanism of Action
R&D Progress
NeisVac-C Prime Boost Vaccine
Product Description
Mechanism of Action
R&D Progress
Preflucel
Product Description
Mechanism of Action
R&D Progress
Whole Virus H5N1 Influenza Vaccine
Product Description
Mechanism of Action
R&D Progress
Baxter International Inc. – Pipeline Analysis
Baxter International Inc. – Pipeline Products by Therapeutic Class
Baxter International Inc. – Pipeline Products By Target
Baxter International Inc. – Pipeline Products by Route of Administration
Baxter International Inc. – Recent Pipeline Updates
Baxter International Inc. - Dormant Projects
Baxter International Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
BAX 499
H. Lundbeck A/S – Company Statement
H. Lundbeck A/S – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
H. Lundbeck A/S - Key Manufacturing Facilities
H. Lundbeck A/S, Recent Developments
H. Lundbeck A/S- Press Release
May 16, 2012: Baxter Receives Chinese Approval For ADVATE For Treatment Of Hemophilia A
Apr 27, 2012: Baxter Presents Efficacy And Safety Data Evaluating Gammagard Liquid For Multifocal Motor Neuropathy At AAN Annual Meeting
Apr 16, 2012: Baxter And Halozyme Provide Update On HyQ Biologics License Application
Mar 04, 2012: Baxter Presents Long-Term Data on HyQ During AAAAI Annual Meeting
Mar 02, 2012: Baxter Receives European Marketing Authorization For VEPACEL Pre-Pandemic Influenza Vaccine
Feb 28, 2012: Baxter Initiates Phase III Adult Stem Cell Clinical Trial For Chronic Cardiac Condition
Jan 23, 2012: Baxter To Initiate Second Phase III Trial Studying GAMMAGARD LIQUID For Treatment Of Alzheimer's Disease
Jan 17, 2012: Natural Enzyme Provides Potential New Approach For Treating Graft-vs-Host-Disease
Jan 09, 2012: Baxter Submits Application For FDA Approval Of GAMMAGARD LIQUID To Treat Multifocal Motor Neuropathy
Jan 05, 2012: Baxter Initiates Phase I Clinical Trial Of Recombinant FVIII Treatment For Hemophilia A
Oct 15, 2009: Baxter H1N1 Vaccine Celvapan to German Soldiers
Oct 07, 2009: Baxter Receives European Commission Approval For CELVAPAN H1N1
Oct 02, 2009: Baxter Receives EMEA Positive Opinion for CELVAPAN H1N1 Pandemic Influenza Vaccine.
Oct 02, 2009: Baxter Receives Positive Opinion For CELVAPAN H1N1 Influenza Vaccine
Aug 05, 2009: Baxter Completes Production Of A/H1N1
Aug 05, 2009: Baxter Completes Production of First Commercial Batches of A/H1N1 Pandemic Vaccine
Aug 05, 2009: Baxter Receives European Commission Approval for CELVAPAN H1N1 Pandemic Influenza Vaccine
Jul 15, 2009: Baxter And Halozyme Announces Completion Of Patient Enrollment In Phase III Pivotal Trial Of GAMMAGARD LIQUID With rHuPH20 Enzyme
Jun 12, 2009: Baxter Advances For Full-Scale Production Of A/H1N1 Vaccine
Mar 16, 2009: Data Presented at AAAAI Reinforce Baxter's Commitment to Making GAMMAGARD LIQUID Therapy More Convenient
Jan 15, 2009: Baxter Collaborates with MedicAlert to Expand Awareness of Glucose Monitor Interference to Enhance Safety in Hospitals
Jan 05, 2009: Phase III Trial Begins For GAMMAGARD LIQUID Plus rHuPH20 In Primary Immunodeficiency Patients.
Financial Deals Landscape
Baxter International Inc., Deals Summary
Baxter International Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Baxter International Acquires Ostene Product Line From Ceremed
Baxter International Acquires Hemophilia-Related Assets From Archemix
Baxter International Acquires Hemofiltration Product Line From Edwards Lifesciences
Baxter Healthcare Acquires Rights To AV513 From Avigen
Synovis Life Technologies Acquires 4Closure System from Fascia Closure Systems
Venture Financing
KaloBios Pharma Secures $32 Million In Series D Financing
ApaTech Secures $45 Million In Financing
ApaTech Raises $11.6 Million In Series B Financing
ApaTech Secures $4.24 Million In Sereis A Financing
Private Equity
3i Group To Sell ApaTech To Coller Capital, HarbourVest Partners And DFJ Esprit
Baxter International Sells Transfusion Therapies Business To Texas Pacific And Maverick Capital
Partnerships
ApaTech Signs Licensing Agreement With The University of Aberdeen
Baxter Healthcare Enters Into Licensing Agreement With Innocoll Pharma
Baxter Healthcare Enters Into Licensing Agreement With Spinal Restoration
Baxter International Enters Into Licensing Agreement With Intercytex
Prism Pharmaceuticials Enters Into Licensing Agreement With CyDex Pharma
Innovata Signs An Agreement With Baxter International
Kuros Biosurgery Signs Licensing Agreement With Baxter International
Debiotech Signs An Agreement With Baxter Healthcare
Baxter International Enters Into Co-Development Agreement With Momenta Pharma For Biologics
Medgenics Extends Co-Development Agreement With Baxter Healthcare
Hanmi Pharma Enters Into Co-Marketing Agreement With Baxter
Cerner Enters Into Co-Marketing Agreement With Baxa
Baxter International Enters Into Distribution Agreement With Kamada For Glassia
Medgenics Enters Into Co-Development Agreement With Baxter Healthcare
Baxter Healthcare Enters Into An Agreement With NIKKISO
Baxter International Enters Into Co-Development Agreement With Flamel Technologies
Baxter International Enters Into A Distribution Agreement With SIGMA International
Angiotech Pharma Enters Into An Agreement With Baxter International
Jerini Enters Into Research Collaboration With Baxter
Baxter Healthcare Signs An Agreement With Nycomed International Management
Nektar Therapeutics Enters Into Co-Development Agreement With Baxter International
Baxter Healthcare Signs Agreement With Pfizer
Halozyme Enters Into Agreement With Baxter For GAMMAGARD LIQUID 10%
Baiyunshan And Baxter Form A Joint Venture In China
Baxter International Enters Into Collaboration With DEKA Research & Development And HHD
Cadence Pharma Enters Into A Development Agreement With Baxter Healthcare
Halozyme Expands Its Agreement With Baxter Healthcare
Baxa Enters Into Co-Marketing Agreement With VIASYS MedSystems
GenOdyssee Enters Into Co-Development Agreement With Baxter
Synovis Life Technologies Signs An Agreement With Caldera Medical
ApaTech Enters Into Distribution Agreement With TranS1
Prism Pharma Enters Into Co-Development Agreement With CyDex Pharma
Synovis Life Technologies Signs An Agreement With S&T
Cerus Signs An Agreement With Baxter International
Nektar Therapeutics Enters Into Co-Development Agreement With Baxter International
Lipoxen Enters Into Research Agreement With Baxter
Halozyme Expands Co-Marketing Agreement With Baxter Healthcare
Gambro Signs An Agreement With Baxter International
Cerus And Baxter International Enters Into An Agreement With BioOne
Halozyme Enters Into Agreement With Baxter
Baxter Schweiz Enters Into Co-Marketing Agreement With Cangene
Althea Technologies Extends Co-Promotion Agreement With Baxter Healthcare
Baxter International Signs An Agreement With Cerus
ApaTech Enters Into Distribution Agreement With Surgicraft
Zimmer Holdings Signs An Agreement With Baxter Healthcare
Baxter And Cerus Enter Into An Agreement With BioOne
Halozyme Therapeutics Enters Into Co-Marketing Agreement With Baxter Healthcare
Morphotek Enters Into Co-Development Agreement With Baxter
Jerini Extends Co-Development Agreement With Baxter Healthcare
Baxter Healthcare Enters Into Co-Promotion Agreement With InterMune
Lupin Enters Into Co-Marketing Agreement With Baxter
Dyax Enters Into Research Collaboration Agreement With Baxter
Licensing Agreements
Baxter International Expands Its Licensing Agreement With Takeda Pharma
Accentia Enters Into Licensing Agreement With Baxter Healthcare
Baxter International Enters Into Licensing Agreement With Archemix
Baxter Enters Into Licensing Agreement With Kamada For GLASSIA
Baxter Enters Into Licensing Agreement With Takeda
Baxter International Enters Into Licensing Agreement With KAKETSUKEN
BioVeris Enters Into Technology Licensing Agreement With Baxter Healthcare
BioVeris Enters Into Licensing Agreement With Baxter Healthcare
Lipoxen Enters Into Licensing Agreement With Baxter
Commonwealth Enters Into Licensing Agreement With Prism
BioVeris Enetrs Into Licensing Agreement With Baxter Healthcare
Penwest Pharma Enters Into Licensing Agreement With Prism Pharma
Baxter Healthcare Enters Into Licensing Agreement With Teva Pharma
Equity Offering
Lipoxen Completes Private Placement Of $4.6 Million
Prism Pharma Secures $23 Million In Private Equity Round
Debt Offering
Baxter International Completes Public Offering Of Senior Notes Due 2017 For $500 Million
Baxter International Completes Public Offering Of 4.25% Senior Unsecured Notes For $300 Million
Baxter International Completes Public Offering Of 1.8% Senior Unsecured Notes For $300 Million
Baxter International Completes Public Offering Of 4.5% Senior Notes For $500 Million
Baxter International Completes Public Offering Of 4% Senior Notes For $350 Million
Baxter International Completes Public Offering Of 5.375% Senior Notes For $500 Million
Baxter International Completes Public Offering Of 6.25% Senior Notes For $500 Million
Baxter International Completes Public Offering Of 5.9% Senior Notes For $600 Million
Asset Transactions
Hikma Pharma Acquires The US Generic Injectables Business From Baxter Healthcare
Bioniche Acquires ENLON and ENLON-PLUS From Baxter
Synovis Life Technologies Sells Its Interventional Business To Heraeus Vadnais
B. Braun Avitum Acquires Renal Therapy Business Of Baxter International
ZIOPHARM Oncology Acquires Indibulin From Baxter Healthcare
Vital Signs Acquires Disposable Airway Management Device Business From Baxter International
Insmed Acquires Manufacturing Facility From Baxter International
B. Braun Avitum Group Acquires Four Dialysis Centers From Baxter Renal Business
Acquisition
Baxter International Acquires Remaining 60% Stake In Sigma International General Medical Apparatus For $90 Million
Baxter International Completes Acquisition Of Synovis Life Technologies For $325 Million
Baxter International Completes Acquisition Of Baxa For $380 Million
Baxter International Completes Acquisition Of Prism Pharma For $338 Million
Baxter International Completes Acquisition Of ApaTech
Synovis Life Technologies Completes Acquisition Of Pegasus Biologics From Comerica Bank
Baxter Healthcare Acquires Willow Healthcare
Baxter International Completes Acquisition Of 40% Interest In SIGMA International General Medical Apparatus
Baxa Acquires ForHealth Technologies

Appendix

Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Baxter International Inc., Key Information
Baxter International Inc., Key Facts
Baxter International Inc. – Pipeline by Indication, 2012
Baxter International Inc. – Pipeline by Stage of Development, 2012
Baxter International Inc. – Monotherapy Products in Pipeline, 2012
Baxter International Inc. – Combination Treatment Modalities in Pipeline, 2012
Baxter International Inc. – Filed, 2012
Baxter International Inc. – Phase III, 2012
Baxter International Inc. – Phase II, 2012
Baxter International Inc. – Phase I, 2012
Baxter International Inc. – Pre-Clinical, 2012
Baxter International Inc. – Pipeline By Therapeutic Class, 2012
Baxter International Inc. - Pipeline By Target, 2012
Baxter International Inc. – Pipeline By Route of Administration, 2012
Baxter International Inc. – Recent Pipeline Updates, 2012
Baxter International Inc. - Dormant Developmental Projects,2012
Baxter International Inc. - Discontinued Pipeline Products, 2012
Baxter International Inc., Other Locations
Baxter International Inc., Subsidiaries
Baxter International Inc., Key Manufacturing Facilities
Baxter International Inc., Deals Summary
Baxter International Acquires Ostene Product Line From Ceremed
Baxter International Acquires Hemophilia-Related Assets From Archemix
Baxter International Acquires Hemofiltration Product Line From Edwards Lifesciences
Baxter Healthcare Acquires Rights To AV513 From Avigen
Synovis Life Technologies Acquires 4Closure System from Fascia Closure Systems
KaloBios Pharma Secures $32 Million In Series D Financing
ApaTech Secures $45 Million In Financing
ApaTech Raises $11.6 Million In Series B Financing
ApaTech Secures $4.24 Million In Sereis A Financing
3i Group To Sell ApaTech To Coller Capital, HarbourVest Partners And DFJ Esprit
Baxter International Sells Transfusion Therapies Business To Texas Pacific And Maverick Capital
ApaTech Signs Licensing Agreement With The University of Aberdeen
Baxter Healthcare Enters Into Licensing Agreement With Innocoll Pharma
Baxter Healthcare Enters Into Licensing Agreement With Spinal Restoration
Baxter International Enters Into Licensing Agreement With Intercytex
Prism Pharmaceuticials Enters Into Licensing Agreement With CyDex Pharma
Innovata Signs An Agreement With Baxter International
Kuros Biosurgery Signs Licensing Agreement With Baxter International
Debiotech Signs An Agreement With Baxter Healthcare
Baxter International Enters Into Co-Development Agreement With Momenta Pharma For Biologics
Medgenics Extends Co-Development Agreement With Baxter Healthcare
Hanmi Pharma Enters Into Co-Marketing Agreement With Baxter
Cerner Enters Into Co-Marketing Agreement With Baxa
Baxter International Enters Into Distribution Agreement With Kamada For Glassia
Medgenics Enters Into Co-Development Agreement With Baxter Healthcare
Baxter Healthcare Enters Into An Agreement With NIKKISO
Baxter International Enters Into Co-Development Agreement With Flamel Technologies
Baxter International Enters Into A Distribution Agreement With SIGMA International
Angiotech Pharma Enters Into An Agreement With Baxter International
Jerini Enters Into Research Collaboration With Baxter
Baxter Healthcare Signs An Agreement With Nycomed International Management
Nektar Therapeutics Enters Into Co-Development Agreement With Baxter International
Baxter Healthcare Signs Agreement With Pfizer
Halozyme Enters Into Agreement With Baxter For GAMMAGARD LIQUID 10%
Baiyunshan And Baxter Form A Joint Venture In China
Baxter International Enters Into Collaboration With DEKA Research & Development And HHD
Cadence Pharma Enters Into A Development Agreement With Baxter Healthcare
Halozyme Expands Its Agreement With Baxter Healthcare
Baxa Enters Into Co-Marketing Agreement With VIASYS MedSystems
GenOdyssee Enters Into Co-Development Agreement With Baxter
Synovis Life Technologies Signs An Agreement With Caldera Medical
ApaTech Enters Into Distribution Agreement With TranS1
Prism Pharma Enters Into Co-Development Agreement With CyDex Pharma
Synovis Life Technologies Signs An Agreement With S&T
Cerus Signs An Agreement With Baxter International
Nektar Therapeutics Enters Into Co-Development Agreement With Baxter International
Lipoxen Enters Into Research Agreement With Baxter
Halozyme Expands Co-Marketing Agreement With Baxter Healthcare
Gambro Signs An Agreement With Baxter International
Cerus And Baxter International Enters Into An Agreement With BioOne
Halozyme Enters Into Agreement With Baxter
Baxter Schweiz Enters Into Co-Marketing Agreement With Cangene
Althea Technologies Extends Co-Promotion Agreement With Baxter Healthcare
Baxter International Signs An Agreement With Cerus
ApaTech Enters Into Distribution Agreement With Surgicraft
Zimmer Holdings Signs An Agreement With Baxter Healthcare
Baxter And Cerus Enter Into An Agreement With BioOne
Halozyme Therapeutics Enters Into Co-Marketing Agreement With Baxter Healthcare
Morphotek Enters Into Co-Development Agreement With Baxter
Jerini Extends Co-Development Agreement With Baxter Healthcare
Baxter Healthcare Enters Into Co-Promotion Agreement With InterMune
Lupin Enters Into Co-Marketing Agreement With Baxter
Dyax Enters Into Research Collaboration Agreement With Baxter
Baxter International Expands Its Licensing Agreement With Takeda Pharma
Accentia Enters Into Licensing Agreement With Baxter Healthcare
Baxter International Enters Into Licensing Agreement With Archemix
Baxter Enters Into Licensing Agreement With Kamada For GLASSIA
Baxter Enters Into Licensing Agreement With Takeda
Baxter International Enters Into Licensing Agreement With KAKETSUKEN
BioVeris Enters Into Technology Licensing Agreement With Baxter Healthcare
BioVeris Enters Into Licensing Agreement With Baxter Healthcare
Lipoxen Enters Into Licensing Agreement With Baxter
Commonwealth Enters Into Licensing Agreement With Prism
BioVeris Enetrs Into Licensing Agreement With Baxter Healthcare
Penwest Pharma Enters Into Licensing Agreement With Prism Pharma
Baxter Healthcare Enters Into Licensing Agreement With Teva Pharma
Lipoxen Completes Private Placement Of $4.6 Million
Prism Pharma Secures $23 Million In Private Equity Round
Baxter International Completes Public Offering Of Senior Notes Due 2017 For $500 Million
Baxter International Completes Public Offering Of 4.25% Senior Unsecured Notes For $300 Million
Baxter International Completes Public Offering Of 1.8% Senior Unsecured Notes For $300 Million
Baxter International Completes Public Offering Of 4.5% Senior Notes For $500 Million
Baxter International Completes Public Offering Of 4% Senior Notes For $350 Million
Baxter International Completes Public Offering Of 5.375% Senior Notes For $500 Million
Baxter International Completes Public Offering Of 6.25% Senior Notes For $500 Million
Baxter International Completes Public Offering Of 5.9% Senior Notes For $600 Million
Hikma Pharma Acquires The US Generic Injectables Business From Baxter Healthcare
Bioniche Acquires ENLON and ENLON-PLUS From Baxter
Synovis Life Technologies Sells Its Interventional Business To Heraeus Vadnais
B. Braun Avitum Acquires Renal Therapy Business Of Baxter International
ZIOPHARM Oncology Acquires Indibulin From Baxter Healthcare
Vital Signs Acquires Disposable Airway Management Device Business From Baxter International
Insmed Acquires Manufacturing Facility From Baxter International
B. Braun Avitum Group Acquires Four Dialysis Centers From Baxter Renal Business
Baxter International Acquires Remaining 60% Stake In Sigma International General Medical Apparatus For $90 Million
Baxter International Completes Acquisition Of Synovis Life Technologies For $325 Million
Baxter International Completes Acquisition Of Baxa For $380 Million
Baxter International Completes Acquisition Of Prism Pharma For $338 Million
Baxter International Completes Acquisition Of ApaTech
Synovis Life Technologies Completes Acquisition Of Pegasus Biologics From Comerica Bank
Baxter Healthcare Acquires Willow Healthcare
Baxter International Completes Acquisition Of 40% Interest In SIGMA International General Medical Apparatus
Baxa Acquires ForHealth Technologies

List of Figures

Baxter International Inc. – Pipeline by Indication, 2012
Baxter International Inc. – Pipeline by Stage of Development, 2012
Baxter International Inc. – Monotherapy Products in Pipeline, 2012
Baxter International Inc. – Combination Treatment Modalities in Pipeline, 2012
Baxter International Inc. – Pipeline By Therapeutic Class, 2012
Baxter International Inc. - Pipeline By Target, 2012
Baxter International Inc. – Pipeline By Route of Administration, 2012 43

Visitor Comments

All Comments

Change Currency

GBP

EURO

USD

Last Viewed

Baxter International Inc. - Product Pipeline Review - 2012

Healthcare and Medical Company Profiles

Find latest Healthcare and Medical Company Profiles with up to date financial, strategic, operational, SWOT analysis and product information for the leading healthcare and medical companies.

Competitor Tracking

Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.

Become an Affiliate

Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?

Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.

Custom Research

Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.

Healthcare and Medical	Type	Keywords Phrase All Words Any Word
Microsoft Windows users can hold the CTRL Key to select more than one sector or country at a time. Apple users can hold the CMD Key to do the same.	Country	Industry Sector
Publisher	Order By Relevance Date	Published In

Baxter International Inc. - Product Pipeline Review - 2012

Select License Type

Speak to an Advisor

Select License Type

Table of Contents

Visitor Comments

Change Currency

Last Viewed

Healthcare and Medical Company Profiles

Competitor Tracking

Become an Affiliate

Custom Research

News

Market Insights

Companies And Markets

Customer Support

Corporate Accounts

Contact Details

Contrast settings

Text size settings

All
Afghanistan
Africa
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua and Barbuda
Argentina
Armenia
Aruba
Asia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia-Herzegovina
Botswana
Bouvet Island
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean
Cayman Islands
Central African Republic
Central America
Central Europe
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Conch Republic
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
Eastern Europe
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Europe
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Global
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guernsey
Guinea
Guinea Bissau
Guyana
Haiti
Heard Island and McDonald Islans
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote D`Ivoire)
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kurdistan
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Middle East
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North America
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Republic of the Congo
Reunion
Romania
Russia
Rwanda
Saint Barthelemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Scandinavia
Schengen countries
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South America
South Georgia and the South Sandwich Islands
South Korea
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste (East Timor)
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Virgin Islands
Wallis and Futuna Islands
Western Sahara
Yemen
Zambia
Zimbabwe

All
Aerospace
Agriculture, Farming & Raw Materials
Automotive and Parts
Business Services
Chemicals
Construction
Consumer Goods
Defence
Energy and Utilities
Environmental
Finance and Banking
Food and Drink
Healthcare and Medical
Industrial
Information Technology
Leisure
Logistics
Media
Paper and Packaging
Publishing and Printing
Real Estate
Retail
Security
Telecommunications
Textiles and Clothing
Transportation
Travel